- All Targets
- Angiogenesis/Tyrosine Kinase
- Cell Cycle/Checkpoint
- HDAC
- Apoptosis
- PARP
- Aurora/Ksp
- MAPK
- PI3K/Akt/mTOR
- Hormone
- Integrase/CCR5
- Proteases/HSP90/HSP70
- Wnt/Hedgehog/Notch
- Jak/Stat
- Ca/cAMP/Lipid Signaling
- Neuro Signaling
- TGF-beta/Smad Signaling
- GPCR
- SCTR
- SSTR
- CRF receptor
- GCGR
- GHSR
- GRF-R
- Ghrelin receptor
- tachykinin NK1 receptor
- vasopressin receptor
- Angiotensin receptor
- CB1 receptor
- CB2 receptor
- OX receptor
- Beta-1 adrenergic receptor
- Smoothened (Smo)
- Alpha-1 receptor
- A2A adenosine receptor
- mGluR2/mGluR3
- PTGFR
- SGLT
- Opioid receptor
- Dopamine receptor
- Beta-2 adrenergic receptor
- Serotonin receptor
- Muscarinic receptor
- Ion channel
- Cytochrome P450
- Others
- Cancer
- Infection
- Endocrinology
- Metabolic Disease
- Inflammation
- Immunology
- Neurological Disease
- Cardiovascular Disease
Capecitabine (Xeloda)
(SynonymsCaptabin
)Add to Favor
M.Wt: 359.35
Formula: C15H22FN3O6
Solubility: DMSO
Purity: >99%
Storage: at -20℃ 2 years
CAS No.: 154361-50-9
Price and Availability of Capecitabine (Xeloda):
Applications & Customer's Feedback of Capecitabine (Xeloda):
Biological Activity of Capecitabine (Xeloda):
Capecitabine (Xeloda) is an orally-administered chemotherapeutic agent (IC50 = 0.7~5 mM) and prodrug of 5-fluorouracil which is a DNA synthesis inhibitor with an IC50 for 5.0 ± 1.8 μM. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, FdUMP and FUTP by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. Capecitabine is a chemotherapy drug that is given as a treatment for many types of cancer, including bowel cancer, breast cancer|, stomach cancer and oesophageal cancer. [1][2][3][4][5]
References on Capecitabine (Xeloda):
[1] Kolinsky K, et al.Mol Cancer Ther. 2009 Jan;8(1):75-82
[2] Lechleider RJ et al. Clin Cancer Res. 2008 Jul 15;14(14):4378-84
[3] Siegel-Lakhai WS et al. Br J Cancer. 2008 Apr 22;98(8):1320-6
[4] Dell’Erba C et al. Pharmacol Res. 2005 Sep;52(3):271-82.
[5] http://en.wikipedia.org/wiki/Capecitabine
MSDS
Batch S115601: H-NMR HPLC COA
Batch S115602: H-NMR HPLC COA
Batch S115604: H-NMR HPLC COA
AntimetabolitesWe give free samples and rewards to people who would like to provide us useful scientific data(western blot, etc.) See Details
Find Multiple Products by Catalog Number
| Dongfeng Chen, The Rausing Lab |
| "Your product U0126(Cat.NO S1102) works well in our experiments. I hope I can get more excellent products from your company in future." |
| R.B. Cambridge |
| "I have used the chemical that I bought from you(Selleck,PTC-124) and it worked well.So we will eventually be ordering more." |
| Zhenghe John Wang Assistant Professor, Case Western Reserve University |
| "We have purchased LBH-589, Saha and MS-275 from you and they all worked well." |
| Jenny Sun |
| "We used the LBH-589 in our experiments. The compound is easy to use with excellent reproducibility." |
| Yu Wang, Harvard University |
| "The GDC0449 compound worked very well. The results in my hands are equally good as what's been published. Thanks for this great resource for our research." |
| Dung-Fang Lee |
| "Based on our preliminary data, I found MLN8237 and VX-680 have good effects in inhibiting Aurka-maintaining ESC self-renewal in mouse ES cells." |
| Jun 2011 Selleck Latest Catalog | ![]() |


